Last week the Food and Drug Administration (FDA) issued a proposed set of new regulations to further define and update the De Novo review process. Although De Novo review has been available for two decades, for the past 20 years, FDA has sought to implement and manage the De Novo review process by reference directly to the statutory language in the Federal Food, Drug, and Cosmetic Act (FDCA) and guidance documents.
Please see full publication below for more information.